GlassScriptPhysician profile
Elizabeth Burchard
NPI 1174595680
$4,601.02
in general payments reported to CMS, 2019-2025
24 companies · $711 in 2025
The $711 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $18.94 · 2021: $172 · 2022: $319 · 2023: $2,270 · 2024: $851 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Food and Beverage: $1,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Food and Beverage | $1,332.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,858.35 | 2019-2025 | Liletta |
| Astellas Pharma US INC | $385.61 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $317.42 | 2023-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $142.97 | 2019-2025 | |
| Pfizer INC. | $112.90 | 2022-2025 | |
| Coopersurgical, INC. | $111.80 | 2021-2025 | Paragard T 380a |
| Sage Therapeutics, LLC | $84.04 | 2025 | Zurzuvae |
| Myovant Sciences INC. | $76.45 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $63.25 | 2021-2023 | |
| Hologic Sales and Service, LLC | $62.20 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $57.31 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $51.79 | 2023 | Myfembree |
| Daiichi Sankyo INC. | $43.79 | 2022-2024 | Injectafer |
| Supernus Pharmaceuticals, INC. | $43.01 | 2025 | Qelbree |
| Shield Therapeutics INC | $24.69 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $23.63 | 2024 | Exparel |
| Amag Pharmaceuticals, INC. | $19.30 | 2019 | |
| Becton, Dickinson and Company | $18.94 | 2020 | |
| Evofem Biosciences, INC. | $18.89 | 2022 | |
| Boston Scientific Corporation | $18.73 | 2019 | |
| Agile Therapeutics, INC. | $18.58 | 2022 | |
| Exact Sciences Corporation | $17.86 | 2023 | Cologuard Collection Kit |
| Therapeuticsmd, INC. | $15.24 | 2021 | |
| Lupin INC. | $14.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Burchard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.